Combined HRT
Also known as: Femoston, Kliofem, Evorel Conti, Evorel Sequi, Elleste Duet, Angeliq
Preparations combining oestrogen and a progestogen in a single product, available in sequential (mimicking a cycle) or continuous combined (no bleed) formulations. Suitable for women with a uterus who need both oestrogen and progestogen.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Regulatory status is factual context, not a clinical-risk assessment. Laws vary by country.
Community Experiences
0 reports from women who tried Combined HRT
No one has reported on this approach yet.
Be the first to share an experience.
Research Context
Research context compiled from published sources
How does Combined HRT work?
Combines the actions of oestrogen (alleviating menopausal symptoms, protecting bone) and progestogen (protecting the endometrium from oestrogen-driven hyperplasia). Sequential regimens produce a monthly bleed; continuous combined regimens aim for no bleed after an initial settling period.
Research Depth
Well Studied
Extensive human research over many years, including randomized controlled trials.
Long-Term Evidence
Well Characterized
Decades of long-term human-use data are available.
Known Interactions
Reported Contraindicated Populations
Published Dose Ranges
Dose ranges from published research. Individual dosing is context-specific and belongs in a healthcare conversation.
Factual research context from published sources — not a clinical-risk assessment or guidance. Research classifications may change as new data emerges.
Related Approaches
Other approaches tracked on Narrated.
Data last updated: No data yet